News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amgen (AMGN)'s Xgeva Gains National Institute for Clinical Excellence (NICE) Recommendation for Bone Metastasis


8/17/2012 7:02:41 AM

NICE is continuing to recommend Amgen’s Xgeva for certain groups of cancer patients whose disease has spread to their bones. In final draft guidance the watchdog recommends Xgeva (denosumab) as a treatment for people with bone metastases from most solid cancer tumours. Specifically, it recommends the drug in patients with bone metastases from breast cancer and people with bone metastases from solid tumours (other than breast or prostate) that would otherwise be prescribed bisphosphonates. Xgeva works by preventing skeletal-related events from occurring from cancer - but not as an anti-cancer or pain relief treatment.

Read at InPharm.com
Read at Independent
Read at Press Assoc. (PA)
Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES